APLM

ANALYST NOTE: APLM (Apollomics, Inc.) Date: 2026-06-13 Current Price: $13.60

1. Structural Readiness

• Conservative Entry: Not yet triggered. Requires a confirmed close above the consolidation ceiling (breakout level).
• Aggressive/Pre-Breakout Entry: Not actionable on setup alone; currently a "forming" signal.
• Breakout Level: Pending confirmation.
• Current Price: $13.60.
• Extension: Significant. The current price is approximately 3.46x the May 2025 PIPE price ($3.93). This represents a substantial run-up prior to the current consolidation, suggesting the market has already priced in significant optimism or specific catalyst expectations.
• ATR Context: Current ATR is 9.0% (Extreme). This indicates high volatility and elevated risk of whipsaw, consistent with a biotech name in a forming consolidation phase where binary event risk (clinical data, regulatory decisions) is high.

2. Thesis Layer

• Thesis Classification: TACTICAL / SETUP-LED.
• Macro Context: There is no named secular thesis attached to this name as of 2026-06-13. The investment case is not driven by a broad macro theme (e.g., "AI in Drug Discovery" or "Global Aging") but is strictly dependent on the quality of the technical setup and the execution of specific company-level milestones.
• Judgment Criteria: Conviction must be derived solely from the structural readiness of the setup (the "forming" coil) and the fundamental validity of the company's pipeline progress as reported by management. Do not invent a macro narrative; judge the name on its ability to execute its specific clinical and commercial roadmap.

3. Business Overview

• Core Business: Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for oncology.
• Primary Asset: The company is substantially dependent on vebreltinib (referred to as vibratinib in earlier transcripts, likely a naming evolution or specific formulation), a novel, orally active, brain-penetrant, highly specific CMET (c-MET) inhibitor.
• Business Model: The company operates on a "develop and license" model. It retains rights in certain territories while licensing commercialization rights to partners in others.
• *Evidence:* As of the 2026-04-24 filing, the company entered a collaboration with LaunXP for the development and commercialization of vebreltinib in Asia (excluding mainland China, HK, and Macau).
• *Evidence:* In November 2023, the company received conditional approval in China for vebreltinib to treat NSCLC with MET exon 14 skipping mutations.
• Financial Status (as of 2025 Year-End):
• The company reported a net loss of $10.9 million for the year ended December 31, 2025.
• Net cash used in operating activities was $10.4 million.
• Liquidity was supported by a $2.0 million unsecured convertible bridge loan from Chairman/CEO Hung-Wen (Howard) Chen in March 2026.
• A $10.0 million impairment loss was recorded in 2025 due to negative Phase 3 results from a partner (GlycoMimetics) regarding uproleselan, writing down the full value of that intangible asset.
• Pipeline Status (Management Expectations):
• NSCLC (MET Exon 14): Management expects to submit an NDA in 2026 for accelerated approval of vebreltinib as a second-line treatment for NSCLC patients with c-MET amplification, contingent on positive results from the SPARTA trial.
• AML: The Phase 3 bridging study in relapsed/refractory AML was fully enrolled by end of 2023. Management expects to report top-line data in the first half of 2025 (Note: As of June 2026, this data should be mature or reported; the 2026 filing implies the company is now looking forward to the next phase or commercialization).
• Other Programs: The uproleselan program (AML) was impaired due to negative Phase 3 results announced by GlycoMimetics in May 2024.

4. Archetype and Conviction

• Archetype: Deep Value Recovery (with high-risk biotech characteristics).
• *Fit:* The name fits "Deep Value Recovery" not because of low absolute valuation multiples (which are not provided), but because the market has likely over-punished the company for the uproleselan impairment ($10M write-down) and the high cash burn, while the core asset (vebreltinib) remains in a high-potential phase. The "recovery" thesis relies on the successful NDA submission in 2026 and the commercialization of vebreltinib.
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no macro tailwinds).
• Evidence Quality: Moderate. The 2026 filing confirms the impairment and the bridge loan, but the critical clinical data for the AML program (expected H1 2025) is now historical. The 2026 NDA submission is a management expectation, not a completed event.
• Rerating Potential: High, contingent on the 2026 NDA submission and the successful commercialization of vebreltinib. The current price ($13.60) is significantly higher than the 2025 PIPE price ($3.93), suggesting the market is already pricing in a successful outcome.
• Valuation Context: The company is burning cash ($10.4M operating cash flow usage in 2025) and relies on a bridge loan. The valuation is driven entirely by the optionality of the vebreltinib NDA.

5. Invalidations, Strengths, and Gaps

• What Would Invalidate:
• Regulatory rejection of the 2026 NDA submission for vebreltinib.
• Failure to secure additional financing beyond the $2.0M bridge loan, leading to liquidity concerns.
• What Would Strengthen:
• A confirmed breakout above the consolidation ceiling (technical confirmation).
• Positive top-line data from the AML program (if not yet fully integrated into the 2026 narrative) or successful commercial launch of vebreltinib in China.
• New partnership announcements expanding the commercial footprint of vebreltinib.
• Gaps in Evidence:
• Missing: Specific details on the *current* cash runway as of June 2026 (beyond the March 2026 bridge loan).
• Missing: The actual outcome of the AML Phase 3 data (expected H1 2025) is not explicitly detailed in the 2026 filing evidence provided, only the expectation of reporting it.
• Missing: Current revenue figures for 2026 (the filing only details 2025 losses).

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key risks: 1) Liquidity risk if the $2.0M bridge loan is insufficient to fund operations until NDA approval; 2) Regulatory rejection of the 2026 NDA submission; 3) Market has already priced in success given the 3.5x run-up from the 2025 PIPE price. Sizing hint: Position size must be minimal due to extreme ATR and unconfirmed setup; treat as a lottery ticket on the NDA outcome. Expected path: Management expects NDA submission in 2026; if approved, the stock may re-rate higher, but if rejected or delayed, the stock faces significant downside from current levels. Expected horizon: 6 to 12 months (aligned with the NDA decision timeline).